Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors wish to thank Dr Adnan Mansoor for advice on the methodology of Ki67 evaluation in Alberta.

Disclosure statement

RP has received honoraria from Beigene and Kite. CO has received honararia from Janssen, AbbVie, AstraZeneca, Beigene, Novartis, and Incyte Biosciences Canada. LS has received honoraria from Seattle Genetics, Kyowa Kirin and Recordati. SP has received honoraria from Beigne, Novartis, Seattle Genetics, and Sobi. AP has received honoraria from AbbVie, AstraZeneca, Janssen, Roche, Incyte, Beigene, Novartis, Seattle Genetics, and Gilead. DS has received honoraria from Abbvie, AstraZeneca, Amgen, Celgene, Gilead, Janssen, Novartis, Roche, Sandoz, and Teva.

Data availability statement

Data may be available from the authors upon reasonable request.

Additional information

Funding

This study did not receive funding from any source.